BlueStar to build methionine plant in China

21-01-2008 | |
BlueStar to build methionine plant in China

China National BlueStar (Group) Corp. and its France-based subsidiary, Adisseo Group, are planning to set up a new methionine plant in China to meet growing demand in the global market.

BlueStar said on 18 Jan. it would establish the new plant in the
petrochemical industrial area of Tianjin, a northern municipality in the
vicinity of Beijing where raw materials were available. The new plant would be
put into operation in 2011 with a preliminary annual capacity of 70,000 tons.
Its designed total annual capacity was 140,000 tons.

Global
demand
Gerard Deman, Adisseo CEO, said existing production capacity
could hardly meet demand in the global market, especially in Asia. He estimated
the Asian market would take up more than half of global demand growth in the
next decade.

By 2015, the global methionine market will grow by four
percent, driven by an increasing global population that will consume nearly 300
million tons of meat annually. Poultry products, 40 percent of which are
produced in Asia, will account for half of the increase in meat demand,
according to the Food and Agriculture Organization of the United Nations.

Adisseo also plans to invest 20 million euros in its French and Spanish
bases in the coming two years to raise production capacity, according to company
sources.

About BlueStar
As a subsidiary of the
state-owned ChemChina Group Corporation, BlueStar Co. focuses on chemical
products and new materials. It has total assets of 20 billion yuan. In January
2006, BlueStar acquired Adisseo Group, the world’s second largest producer of
methionine. It was the first case of a Chinese enterprise acquiring an overseas
firm in the field.
Last February, BlueStar became the largest Chinese
investor in Europe, after acquiring the France-based specialty chemicals
producer Rhodia Group.

Related websites:
Adisseo Group

To receive more animal feed news, subscribe
here

Correspondents



2/3 articles remaining | Register to continue reading.